The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts
In recent years, the number of allogeneic (Allo) stem cell transplantations (SCTs) has progressively increased worldwide [1,2]. Mobilized peripheral blood (PB) stem cells (PBSCs), compared with bone marrow grafts, have a higher stem cell content, lead to faster engraftment [3,4], and are more convenient for collection and, as a consequence, the use of PBSCs grafts have significantly increased. Initially, there were concerns about mobilization in the allogeneic setting due to normal donor toxicity [5,6] and the risk for graft-versus-host disease in the recipient [7], but studies have demonstrated G-CSFs to be well-tolerated by healthy donors (HDs) without any effects on long-term survival [8].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Massimo Martino, Mercedes Gori, Tiziana Moscato, Virginia Naso, Anna Ferreri, Fabio Provenzano, Barbara Loteta, Maria Cristina Sanguedolce, Giuseppe Console, Antonia Dattola, Giulia Pucci, Massimo Gentile, Antonella Morabito, Anna Grazia Recchia, Giovanni Source Type: research